Press Release

Cellares Announces $255 Million Series C

August 25, 2023

Palo Alto – August 25, 2023 – Cooley advised Cellares, the first integrated development and manufacturing organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, on its $255 million Series C financing. Lawyers Josh Seidenfeld and Will Hong led the Cooley team advising Cellares.

Koch Disruptive Technologies led the financing round, with participation from Bristol Myers Squibb, DFJ Growth, Willett Advisors and existing investors Eclipse, Decheng Capital and 8VC. Cellares will use proceeds from the financing to launch its commercial-scale IDMO Smart Factory, which seamlessly integrates advanced robotics, purpose-built technology and interconnected software.

Cooley has represented Cellares since its formation in 2019.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.